Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy

Inclusion Criteria:

* Documented locally advanced head and neck malignancies for which concurrent chemoradiation has been recommended for definitive or adjuvant treatment
* No history of prior radiotherapy to the head and neck; however, if previous treatment was superficial skin radiotherapy without regional lymph node treatment this will be allowed
* Karnofsky performance status (KPS) \>= 70
* Body mass index \>= 18 kg/m\^2
* No evidence of metastatic disease (M1 disease)
* No G-tube placement prior to initiation of chemoradiation
* Eligible to undergo concurrent chemotherapy as determined by treating medical oncologist
* If a woman is of childbearing potential, a negative serum pregnancy test must be documented prior to proceeding with chemoradiation; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for at least 4 weeks after study treatment
* Ability to understand and willingness to sign a written informed consent
* Able to tolerate the taste of one of the flavors of the oral nutritional supplement Soylent
* Able and willing to participate in the Swallow Preservation Program at the Speech Pathology Clinic
* No evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation

Exclusion Criteria:

* Patients who have previously received therapeutic radiation therapy to the head and neck except for superficial skin radiotherapy is allowed
* Patients who had G-tube placement due to concern for aspiration or due to severe malnutrition in advance of chemoradiation
* Patients underweight in advance of chemoradiation (BMI \< 18 kg/m\^2)
* Patients who refuse to use Soylent oral nutritional supplementation due to its taste or other patient preference reasons
* Patients with allergies to any of the ingredients contained in the nutritional supplement
* Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatment
* Refusal to sign the informed consent
* Refusal to participate in the Swallow Preservation Program prior to start of Soylent if applicable
* Evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation
* Distant metastatic disease (M1 disease)